Oscar Health (OSCR) is back in the spotlight after fresh Wall Street coverage and a new 2026 network deal in South Florida pushed investors to revisit its tech driven ACA exchange strategy and growth path.
See our latest analysis for Oscar Health.
Those new network wins and the recent wave of Wall Street coverage have arrived as momentum turns more constructive, with a roughly 19 percent year to date share price return and a powerful three year total shareholder return above 600 percent, signaling investors are steadily re rating Oscar’s growth story despite some recent pullbacks.
If Oscar’s tech enabled push into healthcare has you thinking more broadly about the sector, it could be a good time to explore healthcare stocks as potential next ideas.
With shares now hovering near fresh analyst targets and policy uncertainty looming over 2026, is Oscar still trading at a discount to its tech driven growth curve, or are markets already pricing in the next leg higher?
With Oscar Health last closing at $16.14 against a most popular narrative fair value of $14.38, the story leans toward a stretched valuation supported by improving fundamentals.
The analysts have a consensus price target of $11.143 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $8.0.
Curious how modest top line growth, margin repair, and a richer future earnings multiple combine to justify this punchy fair value gap? The narrative explains the full math behind that call in detail.
Result: Fair Value of $14.38 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, aggressive repricing, AI driven efficiencies, and expanding chronic condition products could accelerate margin recovery and make today’s stretched valuation assumptions appear too conservative.
Find out about the key risks to this Oscar Health narrative.
While the narrative flags Oscar Health as around 12 percent overvalued versus a $14.38 fair value, its price to sales ratio near 0.4 times tells a different story. That is materially below the US Insurance industry at 1.1 times and peers at 0.7 times, and even undercuts a 0.6 times fair ratio, suggesting the market may still be underpricing its revenue base and long term scaling potential. Is this a margin of safety, or a warning that profits remain too uncertain?
